Novel glycosylated [Lys7]-dermorphin analogues: synthesis, biological activity and conformational investigations
✍ Scribed by Laura Biondi; Fernando Filira; Elisa Giannini; Marina Gobbo; Roberta Lattanzi; Lucia Negri; Raniero Rocchi
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 224 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1075-2617
- DOI
- 10.1002/psc.829
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Syntheses of the [Lys^7^]‐ and [Hyp^6^,Lys^7^]‐dermorphin analogues in which either Tyr^5^ or Hyp^6^ are O‐glucosylated are described. For comparison, the carbohydrate‐free peptides have also been prepared. Structural investigations by FT‐IR and CD measurements were carried out on the synthetic analogues and some preliminary pharmacological experiments were also performed.
The biological potency of the glucosylated analogues was compared with that of the µ‐opioid receptor agonist dermorphin in GPI preparations. Glucosylation of either Tyr^5^ or Hyp^6^ reduces the potency of both [Lys^7^]‐dermorphin and [Hyp^6^,Lys^7^]‐dermorphin. The effect induced by the Tyr^5^ glucosylation is quite strong and the potency of both peptides is reduced by about 150 times. A similar but less dramatic effect is induced by the glucosylation of the Hyp^6^ residue, and the potency of the parent peptide is reduced by about 15 times. The presence of acetyl groups on the sugar hydroxyl functions further reduces the agonistic potency of the glucosylated analogues. The analgesic potency of [Hyp^6^,Lys^7^]‐, [Hyp(βGlc)^6^,Lys^7^]‐ and [Tyr(βGlc)^5^,Lys^7^]‐dermorphin were also tested in vivo by the tail‐flick test. The glucosylated hydroxyproline‐containing analogue is 8–10 times less active than the parent peptide, but its analgesic effect lasts significantly longer. Copyright © 2006 European Peptide Society and John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract The synthesis is described of a [D‐Ala^2^]‐deltorphin I peptoid analogue in which all amino acid residues have been substituted by the corresponding __N__‐alkylglycine residues. The [D‐Ala^2^]‐deltorphin I retropeptoid was also prepared as well as [Ala^1^,D‐Ala^2^]‐deltorphin 1 and the
## Abstract Vasoactive intestinal peptide (VIP) is a prominent neuropeptide, exhibiting a wide spectrum of biological activities in mammals. However, the clinical applications of VIP are mainly hampered because of its rapid degradation __in vivo__. Peptide glycosylation, a procedure frequently used
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v
## Abstract Syntheses are described of new dermorphin and [D‐Ala^2^]deltorphin I analogues in which the phenylalanine, the tyrosine or the valine residues have been substituted by the corresponding __N__‐alkyl‐glycine residues. Structural investigations by CD measurements in different solvents and